key: cord-0792118-2x3rorbh
authors: Chiem, Kevin; Vasquez, Desarey Morales; Silvas, Jesus A.; Park, Jun-Gyu; Piepenbrink, Michael S.; Sourimant, Julien; Lin, Michelle J.; Greninger, Alexander L.; Plemper, Richard K.; Torrelles, Jordi B.; Walter, Mark R.; de la Torre, Juan C.; Kobie, James K.; Ye, Chengjin; Martinez-Sobrido, Luis
title: A bifluorescent-based assay for the identification of neutralizing antibodies against SARS-CoV-2 variants of concern in vitro and in vivo
date: 2021-06-28
journal: bioRxiv
DOI: 10.1101/2021.06.28.450214
sha: fdfce52fb50d489d7d4bf1f1bdba2f8db20d9b1a
doc_id: 792118
cord_uid: 2x3rorbh

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and has been responsible for the still ongoing coronavirus disease 2019 (COVID-19) pandemic. Prophylactic vaccines have been authorized by the United States (US) Food and Drug Administration (FDA) for the prevention of COVID-19. Identification of SARS-CoV-2 neutralizing antibodies (NAbs) is important to assess vaccine protection efficacy, including their ability to protect against emerging SARS- CoV-2 variants of concern (VoC). Here we report the generation and use of a recombinant (r)SARS-CoV-2 USA/WA1/2020 (WA-1) strain expressing Venus and a rSARS-CoV-2 expressing mCherry and containing mutations K417N, E484K, and N501Y found in the receptor binding domain (RBD) of the spike (S) glycoprotein of the South African (SA) B.1.351 (beta, β) VoC, in bifluorescent-based assays to rapidly and accurately identify human monoclonal antibodies (hMAbs) able to neutralize both viral infections in vitro and in vivo. Importantly, our bifluorescent-based system accurately recapitulated findings observed using individual viruses. Moreover, fluorescent- expressing rSARS-CoV-2 and the parental wild-type (WT) rSARS-CoV-2 WA-1 had similar viral fitness in vitro, as well as similar virulence and pathogenicity in vivo in the K18 human angiotensin converting enzyme 2 (hACE2) transgenic mouse model of SARS-CoV-2 infection. We demonstrate that these new fluorescent-expressing rSARS- CoV-2 can be used in vitro and in vivo to easily identify hMAbs that simultaneously neutralize different SARS-CoV-2 strains, including VoC, for the rapid assessment of vaccine efficacy or the identification of prophylactic and/or therapeutic broadly NAbs for the treatment of SARS-CoV-2 infection.

The emergence of SARS-CoV-2 at the end of 2019 has been responsible for the 71 COVID-19 pandemic 1 . Despite numerous efforts to contain viral spread, SARS-CoV-2 72 disseminated worldwide and as of today it has been linked to over 175 million infections 73 and more than 3.8 million deaths around the world 2 . To date, one antiviral drug 74 (NT 50 12.08 and 7.97 ng, respectively) ( Figure 4F ). These results demonstrated the 223 feasibility of using this novel bifluorescent-based assay to readily and reliably identify 224 hMAbs with neutralizing activity against both SARS-CoV-2 strains within the same 225 assay and that these results recapitulated those of experiments following individual viral 226 infections and classical neutralization assays using natural viral isolates. 227

To further demonstrate the feasibility of this new bifluorescence-based assay to 228 identify hMAbs able to neutralize different SARS-CoV-2 strains present in the same 229 11 sample, we assessed the neutralizing activity of a selected set of previously described 230 hMAbs 22 . CB6, REGN10933, and REGN10987 hMAbs were used as internal controls 231 in the assay 25, 26 . CB6 ( Figure 5A ) and REGN10933 ( Figure 5B ) neutralized rSARS-232

CoV-2 Venus (NT 50 of 1.02 and 1.53 ng, respectively) but exhibited limited 233 (REGN10933, NT 50 > 240.9 ng) or no (CB6, NT 50 > 500 ng) neutralization activity 234 against rSARS-CoV-2 mCherry SA. On the other hand, REGN10987 ( Figure 5C ) 235 efficiently neutralized both rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA (NT 50 236 of 0.63 and 0.18 ng, respectively) ( Figure 5C ). Some of the tested hMAbs were also 237 able to specifically neutralize rSARS-CoV-2 Venus but not rSARS-CoV-2 mCherry SA, 238

including 1206D12 (NT 50 0.58 and > 500 ng, respectively) ( Figure 5D ), 1212D5 (NT 50 239 0.54 and > 500 ng, respectively) ( Figure 5E ), and 1215D1 (NT 50 20.31 and > 500 ng, 240 respectively) ( Figure 5F ). We identified hMAbs with broadly neutralizing activity against 241 both rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA, including 1206G12 (NT 50 of 242 2.23 and 1.18 ng, respectively) ( Figure 5G ), 1212F2 (NT 50 of 31.14 and 10.64 ng, 243 respectively) (Figure 5H) , and 1207B4 (6.45 and 1.05 ng, respectively) ( Figure 5I) . 244

These results support the feasibility of this novel bifluorescent-based assay to identify 245 broad neutralizing hMAbs against different SARS-CoV-2 strains within the same assay. 246

Based on our in vitro results, we hypothesized that our novel bifluorescent-based 248 assay to identify NAbs against different SARS-CoV-2 strains could be adapted to 249 assess the neutralizing activity of hMAbs in vivo. To test this hypothesis, we assessed 250 the ability of 1212C2 and 1213H7 hMAbs to neutralize rSARS-CoV-2 Venus and 251 rSARS-CoV-2 mCherry SA, alone or in combination, in the K18 hACE2 transgenic 12 mouse model of SARS-CoV-2 infection (Figure 6 ) 27 . Mice were treated intraperitoneally 253 (i.p.) with 25 mg/kg of 1212C2, 1213H7, or an IgG isotype control 24 h prior to 254 challenge with 10 4 PFU of rSARS-CoV-2 Venus, rSARS-CoV-2 mCherry SA, or both 255 rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA together. Body weight ( Figure  256 6A) and survival ( Figure 6B ) were evaluated for 12 days post-infection (pi). IgG isotype 257 control-treated mice infected with rSARS-CoV-2 Venus, rSARS-CoV-2 mCherry SA, or 258 both rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA together, exhibited weight 259 loss starting on day 4 pi ( Figure 6A ) and succumbed to viral infection between days 6 260 to 8 pi ( Figure 6B) . However, all mice treated with 1212C2 or 1213H7 survived 261 challenge with rSARS-CoV-2 Venus, consistent with efficient neutralization of SARS-262

CoV-2 WA-1 in vitro by these two hMAbs (Figures 2 and 4) . In contrast, only 1213H7, 263 but not 1212C2, was able to protect mice infected with rSARS-CoV-2 mCherry SA 264 ( Figures 6A and 6B) , consistent with the inability of 1212C2 to neutralize rSARS-CoV-2 265 mCherry SA in vitro (Figure 4) . When mice were co-infected with both rSARS-CoV-2 266

Venus and rSARS-CoV-2 mCherry SA, only mice treated with 1213H7 retained their 267 initial body weight and survived infection (Figures 6A and 6B , right panels), similar to 268 results obtained using individual infections. 269

We next examined whether FP expression could be used as a surrogate of SARS-272

CoV-2 multiplication in the lungs of infected mice, providing a readout to assess the in 273 vivo protective activity of 1212C2 and 1213H7 hMAbs through IVIS (Figure 7) . K18 274 hACE2 transgenic mice were treated (i.p., 25 mg/kg) with IgG isotype control, 1212C2, 275 13 or 1213H7 hMAbs, 24 h before infection (10 4 PFU/mouse) with rSARS-CoV-2 Venus 276 and/or rSARS-CoV-2 mCherry SA, singly or in combination. Mock-infected mice were 277 included as control. At days 2 and 4 pi, Venus and mCherry expression in the lungs was 278 evaluated using IVIS ( Figure 7A ) and quantified using Aura imaging software ( Corroborating our previous in vitro and in vivo results (Figures 4 and 6 , respectively), 293 mice treated with 1213H7 were protected against infection with both rSARS-CoV-2 294

Venus and rSARS-CoV-2 mCherry SA, when administered alone or in combination, and 295 presented no detectable fluorescence in the lungs ( Figure 7A) . These data were further 296 supported by quantification of the average radiant efficiency of fluorescence signals, 297 which were high in the lungs of IgG isotype control-treated mice infected with rSARS-298 14 CoV-2 Venus or rSARS-CoV-2 mCherry SA, and in the lungs of 1212C2-treated mice 299 infected with rSARS-CoV-2 mCherry SA ( Figure 7B) . Importantly, gross pathological 300 scoring correlated with levels of FP expression in the lungs of infected mice. 301

As predicted, IgG isotype control-treated K18 hACE2 transgenic mice infected with 302 rSARS-CoV-2 Venus (Figure 8A) , rSARS-CoV-2 mCherry SA ( Figure 8B ), or both 303 rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA ( Figure 8C ) presented high viral 304 titers. In contrast, lungs of 1212C2-treated and infected mice had undetectable levels of 305 rSARS-CoV-2 Venus ( Figure 8A ), but high titers of rSARS-CoV-2 mCherry SA when 306 mice were individually infected ( Figure 8B ) or co-infected with both viruses ( Figure 8C) . 307

In 1213H7-treated and infected mice, we did not detect rSARS-CoV-2 Venus (Figure 308 (Figures 4 and 6 , respectively), 311

Lung homogenates from IgG isotype control-treated mice infected with both reporter 312 viruses contained ~25% and ~75% of Venus and mCherry, respectively, positive 313 plaques by day 2 pi. This finding suggested that rSARS-CoV-2 mCherry SA had a 314 higher fitness than rSARS-CoV-2 Venus in vivo ( Figure 8D) , which was similar to our in 315 vitro studies (Figure 3) . Notably, by day 4 pi all viral plaques were mCherry-positive, 316 further supporting a higher fitness of rSARS-CoV-2 mCherry SA compared to rSARS-317

CoV-2 Venus in vivo ( Figure 8D ). Lung homogenates from 1212C2-treated mice 318 contained rSARS-CoV-2 mCherry SA, reflecting the ability of 1212C2 to efficiently 319 neutralize rSARS-CoV-2 Venus but not rSARS-CoV-2 mCherry SA. In contrast, no viral 320 plaques were detected in lung homogenates from mice treated with 1213H7, as this There is limited information on the ability of current vaccines to protect against these 357 newly identified SARS-CoV-2 VoC 9,10,33 . Moreover, it is likely that additional VoC will 358 emerge in the future. CoV-2 resulted in higher FP expression levels than those afforded by rSARS-CoV-2 369 expressing FPs from the locus of the viral ORF7a protein 20 . Moreover, rSARS-CoV-2 370 expressing reporter genes from the N locus are more genetically stable than those 371 expressing reporter genes from the ORF7a locus of the SARS-CoV-2 genome 20 . 372

We showed that rSARS-CoV-2 expressing Venus or mCherry from the N locus 373 exhibited similar growth kinetics, peak titers, and plaque phenotype as the parental WT 374 rSARS-CoV-2 WA-1 strain. Importantly, we were able to use these novel reporter 375 rSARS-CoV-2 in bifluorescent-based assays to determine the neutralization efficacy of 376 hMAbs based on FP expression levels. We also generated rSARS-CoV-2 mCherry SA, 377

an mCherry-expressing rSARS-CoV-2 containing the K417N, E484K, and N501Y 378 mutations in the RBD of the S glycoprotein of the SA VoC. Notably, rSARS-CoV-2 379 mCherry SA had higher fitness than rSARS-CoV-2 Venus in cultured cells, as 380 evidenced by higher viral titers reached and a bigger plaque size phenotype. 381

Interestingly, when used in the bifluorescent-based assay, hMAb 1212C2 was unable to 382 neutralize rSARS-CoV-2 mCherry SA, but efficiently neutralized rSARS-CoV-2 Venus. 383

In contrast, hMAb 1213H7 displayed efficient neutralization of both rSARS-CoV-2 384

Venus and rSARS-CoV-2 mCherry SA. Importantly, these in vitro results correlated with 385 in vivo studies in which K18 hACE2 transgenic mice pre-treated with 1212C2 were 386 protected against challenge with rSARS-CoV-2 Venus but not rSARS-CoV-2 mCherry 387 SA, alone or in combination. In contrast, mice treated with 1213H7 were protected 388 against lethal challenge with both reporter-expressing rSARS-CoV-2, alone or in To confirm the identity of the rescued rSARS-CoV-2 mCherry SA, total RNA from 458 infected (MOI 0.01) Vero E6 cells (1.2 x 10 6 cells/well, 6-well format, triplicates) was 459 21 extracted using TRIzol reagent (Thermo Fisher Scientific), and used in RT-PCR 460 reactions to amplify a fragment of 1,174 bp around the RBD of the S gene. RT-PCR 461 was done using SuperScript II reverse transcriptase (Thermo Fisher Scientific) and 462

Expand high-fidelity PCR system (Sigma-Aldrich). RT-PCR products were purified on 463 0.7% agarose gel and subjected to Sanger sequencing (ACGT). All primer sequences 464 are available upon request. 

Confluent monolayers of Vero E6 cells (2 x 10 5 cells/well, 24-well plate format, 491 triplicates) were infected with WT or reporter-expressing rSARS-CoV-2 for 1 h before 492 being overlaid with pi media containing 1% agar (Oxoid) and incubated at 37ºC in a 5% 493 CO 2 incubator. After 72 h, cells were fixed in 10% neutral buffered formalin overnight at 494 4ºC. Next, overlays were removed, PBS was added to each well, and fluorescent 495 plaques were detected and quantified using a ChemiDoc MP imaging system (Bio-Rad). 496

Cells were then permeabilized with 0.5% Triton X-100 in PBS for 5 min, blocked with 497 2.5% BSA in PBS for 1 h, and incubated with the SARS-CoV N mMAb 1C7C7, and 498 plaques detected using a Vectastain ABC kit and DAB HRP Substrate kit (Vector 499 laboratories) following the manufacturers' instructions. 500

The hMAbs used in this study were generated and purified as described 22 . CB6, 502 REGN10987 and REGN10933 hMAbs were included as controls 25, 26 . To test the 503 neutralizing activity of hMAbs, confluent monolayers of Vero E6 cells (4 x 10 4 cells/well, 504 96-plate well format, quadruplicates) were infected (MOI of 0.01 or 0.1) with the 505 23 indicated rSARS-CoV-2 for 1 h at 37°C. After viral absorption, pi media containing 3-fold 506 dilutions of the indicated hMAbs (starting concentration of 500 ng/well) were added to 507 the cells and incubated at 37ºC for 48 h. Cells were then fixed in 10% neutral buffered 508 formalin overnight and washed with PBS, before fluorescence signal was measured and 509 quantified using a Synergy LX microplate reader and Gen5 data analysis software (Bio-510

Tek). The mean and SD of viral infections were calculated from individual wells of three 511 independent experiments conducted in quadruplicates with Microsoft Excel software. 512

Non-linear regression curves and NT 50 values were determined using GraphPad Prism 513

Software (San Diego, CA, USA, Version 8.2.1). Representative images were captured 514 with an EVOS M5000 Imaging system (Thermofisher) at 10X magnification. 515

All animal protocols were approved by Texas Biomed IACUC (1718MU). Six-to-517 eight-week-old female K18 human angiotensin converting enzyme 2 (hACE2) 518 transgenic mice were purchased from The Jackson Laboratory and maintained in the 519 Animal Biosafety Laboratory level 3 (ABSL-3) at Texas Biomedical Research Institute. 520

All mouse procedures were approved by Texas Biomedical Research Institute IACUC. 521

To assess the in vivo efficacy of hMAbs, K18 hACE2 transgenic mice (n=5/group) were 522 anesthetized with isoflurane and injected (i.p.) with hMAbs IgG isotype control, 1212C2 523 or 1213H7 (25 mg/kg) using a 1 ml syringe 23-25 gauge 5/8 inch needle 24 h prior to 524 challenge with rSARS-CoV-2. For viral challenges, mice were anesthetized and 525 inoculated intranasally (i.n.) with 10 4 plaque forming units (PFU) of the indicated rSARS-526

CoV-2 and monitored daily for morbidity as determined by changes in body weight, and 527

survival. Mice that lost greater than 25% of their initial weight were considered to have 528 24 reached their experimental endpoint and were humanely euthanized. In parallel, K18 529 hACE2 transgenic mice (n=3/group) were treated (i.p.) with 1212C2 or 1213H7 hMAbs 530 and challenged i.n. with 10 4 PFU of the indicated rSARS-CoV-2 for viral titer 531

determination. Viral titers in the lungs of infected mice at days 2 and 4 pi were 532 determined by plaque assay. In vivo fluorescence imaging of mouse lungs was 533 conducted using an Ami HT in vivo imaging system, IVIS (Spectral Instruments). Mice 534 were euthanized with a lethal dose of Fatal-Plus solution and lungs were surgically 535 extracted and washed in PBS before imaging in the Ami HT. Images were analyzed with 536

Aura software to determine radiance with the region of interest (ROI), and fluorescence 537 signal was normalized to background signal of lungs from mock-infected mice. Bright 538 field images of lungs were captured using an iPhone X camera. After imaging, lungs 539 were homogenized using a Precellys tissue homogenizer (Bertin Instruments) in 1 ml of 540 PBS and centrifuged at 21,500 x g for 10 min to pellet cell debris. Clarified supernatants 541 were collected and used to determine viral titers by plaque assay. Macroscopic 542 pathological scoring was determined from the percent of total surface area affected by 543 congestion, consolidation, and atelectasis of excised lungs, using NIH ImageJ software 544 as previously described 21, 35 . 545

All data are presented as mean values and SD for each group and were analyzed 547 using Microsoft Excel software. A two-tailed Student t test was used to compare the 548 means between two groups. A P value of less than 0.05 (P<0.05) was considered 549 statistically significant. 550

All of the data supporting the findings of this work can be found within the paper. 552

The raw data are available from the corresponding authors upon request. rSARS-CoV-2 mCherry, alone or together, and tissue cultured supernatants were 611 collected at the indicated times pi to assess viral titers using standard plaque assay (D). 612

The amount of Venus-and/or mCherry-positive rSARS-CoV-2 at the same times pi in 613 cells infected with both viruses were also determined using plaque assay (E). Images of 614 infected cells under a fluorescent microscope at the same times pi are shown (F). G) 615

Plaque assays: Vero E6 cells (6-well plate format, 10 6 cells/well, triplicates) were mock-616 infected or infected with ~20 PFU of rSARS-CoV-2, rSARS-CoV-2 Venus, rSARS-CoV-617 2 mCherry, or both rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry. At 72 hpi, 618 fluorescent plaques were assessed using a Chemidoc instrument. Viral plaques were 619 also immunostained with the SARS-CoV N protein 1C7C7 cross-reactive mMAb. Venus and rSARS-CoV-2 mCherry SA: Six-to-eight-week-old female K18 hACE2 694 transgenic mice (n=3) were injected (i.p.) with 25 mg/kg of an IgG isotype control, hMAb 695

Venus, or rSARS-CoV-2 mCherry SA. Infected cells were fixed in 10% 644 neutral buffered formalin at 24 hpi and visualized under a fluorescence microscope for

Venus or mCherry expression. D-F) Multicycle growth kinetics: Vero E6 cells (6-well 646 plate format, 10 6 cells/well, triplicates) were mock-infected or infected

Venus, rSARS-CoV-2 mCherry SA, or both rSARS-CoV-2 Venus and 648 rSARS-COV-2 mCherry SA. Tissue cultured supernatants were collected at the 649 indicated times pi to assess viral titers using standard plaque assay (D)

Images of infected cells under a fluorescent microscope at 652 the same times pi are shown (F). G) Plaque assays: Vero E6 cells (6-well plate format, 653 10 6 cells/well, triplicates) were mock-infected or infected with ~20 PFU of rSARS-CoV-2, 654 rSARS-CoV-2 Venus, rSARS-CoV-2 mCherry SA, or both rSARS-CoV-2 Venus and 655 rSARS-CoV-2 mCherry SA. At 72 hpi, fluorescent plaques were assessed using a 656 Chemidoc instrument. Viral plaques were also immunostained with the SARS-CoV N 657 protein 1C7C7 cross-reactive mMAb. Fluorescent green, red and merge imaged as 658 shown

Figure 4. A bifluorescent-based assay to identify SARS-CoV-2 broadly NAbs

Confluent monolayers of Vero E6 cells (4 x 10 4 cells/well, 96-plate well format, 661 quadruplicates) were infected (MOI 0.1) with rSARS-CoV-2 Venus (A and D)

After 1 h infection, pi media 664 containing 3-fold serial dilutions of 12C2C2 (A-C) or 1213H7 (D-F) hMAbs (starting 665 concentration 500 ng) was added to the cells

1212C2, or hMAb 1213H7 and infected with 10 4 PFU of rSARS-CoV-2 Venus (top)

rSARS-CoV-2 mCherry SA (middle), or both, rSARS-CoV-2 Venus and rSARS-CoV-2

At days 2 and 4 pi, lungs were collected to determine Venus and 698 mCherry fluorescence expression using an Ami HT imaging system (A). BF, bright field

Mean values were normalized to the 701 autofluorescence in mock-infected mice at each time point and were used to calculate 702 fold induction. Gross pathological scores in the lungs of mock-infected and rSARS-CoV-703 2-infected K18 hACE2 transgenic mice were

Figure 8. Viral titers in the lungs, nasal turbinate and brain of K18 hACE2 706 transgenic mice treated with 1212C2 or 1213H7 hMAbs and infected with rSARS

Six-to-eight-week-old female K18 708 hACE2 transgenic mice (n=3) injected (i.p.) with 25 mg/kg of an IgG isotype control, 709 hMAb 1212C2, or hMAb 1213H7, and infected with 10 4 PFU of rSARS-CoV-2 Venus 710 (A), rSARS-CoV-2 mCherry SA (B), or both rSARS

nasal turbinate (middle) and brain mean and SD of lung virus titers. Dotted lines indicate the limit of 714 detection. D) Quantification of rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA in 715 the lungs (top), nasal turbinate (middle) and brain (bottom) from mice co-infected with 716 both rSARS-CoV-2 Venus and rSARS-CoV-2 mCherry SA

A Novel Coronavirus from Patients with Pneumonia in China

An interactive web-based dashboard to track

COVID-19 in real time

Remdesivir and chloroquine effectively inhibit the recently 742 emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir for the Treatment of Covid-19 -Final Report

The neutralizing antibody, LY-CoV555, protects against SARS

CoV-2 infection in nonhuman primates

Safety and Efficacy of the BNT162b2 mRNA Covid-19

The Advisory Committee on Immunization Practices' Interim 753 Recommendation for Use of Moderna COVID-19 Vaccine -United States

The Johnson & Johnson Vaccine 757 for COVID-19

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural 759 and vaccine-induced sera

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against 762 the B.1.351 Variant

South Africa, a 2-dose Oxford/AZ vaccine did not 765 prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)

Emergence and rapid spread of a new severe acute respiratory 768 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike 769 mutations in South Africa. medRxiv

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection 772 Gradient in the Respiratory Tract

An Infectious cDNA Clone of SARS-CoV-2

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and 777 screening of anti-infective drugs for COVID-19. bioRxiv

Generation and Characterization of recombinant SARS-CoV-2 780 expressing reporter genes

A novel fluorescent and bioluminescent Bi-Reporter influenza A 782 virus (BIRFLU) to evaluate viral infections

A comprehensive influenza reporter virus panel for high-785 throughput deep profiling of neutralizing antibodies

Rapid in vitro assays for screening neutralizing antibodies and 788 antivirals against SARS-CoV-2

Visualization of SARS-CoV-2 infection dynamic. bioRxiv

Rescue of SARS-CoV-2 from a Single Bacterial Artificial

Therapeutic activity of an inhaled potent SARS-CoV-2 795 neutralizing human monoclonal antibody in hamsters. bioRxiv

Epitope classification and RBD binding properties of neutralizing antibodies 799 against SARS-CoV-2 variants of concern. bioRxiv

SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern 802 induce lethal disease in K18-hACE2 transgenic mice despite convalescent 803 plasma therapy. bioRxiv

Studies in humanized mice and convalescent humans yield a 805 SARS-CoV-2 antibody cocktail

A human neutralizing antibody targets the receptor-binding site of

Lethality of SARS-CoV-2 infection in K18 human 810 angiotensin-converting enzyme 2 transgenic mice

Preliminary genomic characterisation of an emergent SARS

CoV-2 lineage in the UK defined by a novel set of spike mutations

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in

Genomics and epidemiology of a novel SARS-CoV-2 lineage in

Neutralization of variant under investigation B.1.617 with sera 820 of BBV152 vaccinees

Identification of and Surveillance for the SARS-CoV-2

1.427 and B.1.429 -Colorado

SARS-CoV-2 variants, spike mutations and immune escape

Rescue of Recombinant Zika Virus from a Bacterial Artificial Chromosome cDNA

Quantitative analysis of histological staining and fluorescence 830 using ImageJ